Thus, while PD-L1 remains an important biomarker for identifying potential responders to immunotherapy, the role of other biomarkers (e.g., microsatellite instability, tumor mutational burden) and clinical features will need to be further explored. This evidence concerns the gene CD274 and neoplasm.